Additional phase II data backs up Bavarian Nordic's Covid-19 vaccine
Bavarian Nordic is on track with its plan to start phase III trials of its corona vaccine candidate in the first half of this year. New data released on Monday is promising for the candidate.
by marketwire, translated by catherine brett and daniel pedersen
Danish biotech company Bavarian Nordic can once again announce positive results from a phase II study of its corona vaccine, ANBCoV2. The results from two remaining patient groups have now been analyzed and found to support the vaccine’s ability to boost neutralizing antibodies to levels that protect the individual against Covid-19.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Bavarian Nordic on FDA special status: A huge validation
For subscribers
Moderna initiates phase III study of RSV vaccine
For subscribers
